KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBIT (2016 - 2025)

Sarepta Therapeutics has reported EBIT over the past 15 years, most recently at -$411.6 million for Q4 2025.

  • For Q4 2025, EBIT fell 354.56% year-over-year to -$411.6 million; the TTM value through Dec 2025 reached -$699.8 million, down 420.88%, while the annual FY2025 figure was -$699.8 million, 420.88% down from the prior year.
  • EBIT for Q4 2025 was -$411.6 million at Sarepta Therapeutics, down from -$103.4 million in the prior quarter.
  • Over five years, EBIT peaked at $161.7 million in Q4 2024 and troughed at -$411.6 million in Q4 2025.
  • A 5-year average of -$87.3 million and a median of -$104.6 million in 2021 define the central range for EBIT.
  • On a YoY basis, EBIT climbed as much as 16587.45% in 2025 and fell as far as 960.58% in 2025.
  • Year by year, EBIT stood at -$105.8 million in 2021, then fell by 0.96% to -$106.8 million in 2022, then surged by 123.05% to $24.6 million in 2023, then soared by 556.57% to $161.7 million in 2024, then plummeted by 354.56% to -$411.6 million in 2025.
  • Business Quant data shows EBIT for SRPT at -$411.6 million in Q4 2025, -$103.4 million in Q3 2025, and $115.6 million in Q2 2025.